Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 20/20 | 0.98 |
| ▸ | NOS3 | P29474 | 19/20 | 0.98 |
| ▸ | NOS2 | P35228 | 11/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264480 | 0.94 | NOS1 (0.98) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL1122626 | 0.93 | NOS3 (1.00) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL1122008 | 0.87 | NOS1 (1.00) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL2261694 | 0.82 | NOS3 (0.86) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL2262091 | 0.81 | NOS1 (0.98) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL1122441 | 0.80 | NOS1 (1.00) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL1122153 | 0.79 | NOS3 (1.00) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL2262504 | 0.78 | NOS3 (0.75) | NOS1NOS3NOS2CYP3A4CYP2C19 | |
| SCHEMBL2264715 | 0.78 | NOS3 (0.63) | NOS1NOS3NOS2 | |
| SCHEMBL2265547 | 0.78 | NOS1 (0.98) | NOS1NOS3NOS2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| EP-2010527-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2009-01-07 | — | — | EP | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| WO-2007118314-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NOS1, NOS3, NOS2 | NOS1 1/4885NOS3 2/4885NOS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.